Skip to main content
US EQUITIES PRE-MARKET CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
CO

COAGStockHemab Therapeutics Holdings, Inc.

Nasdaq Global Select Market · Healthcare · US

$39.15 last close 2026-11-18
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment COAG's does — no target price to set, unlike a price alert.

Sharia status
NOT YET SCREENED
Not screened yet — no methodology has been established for this symbol
0 of 3 pass our own screen — 4 of 7 could not be computed
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No active setup right now. The technical picture doesn't show a clear edge — check back when the trend or momentum shifts.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure0 of 5 timeframes bullish · 21.7% aligned
VWAPPrice below VWAP ($39.36)
VolumeRelative volume 3.0× the 20-day average
Momentum10-day rate of change -13.2%
Market & analysts
Price target
$63.00
+60.9% · 7 analysts
Institutional own.
99.5%
of shares
Momentum (10d)
-13.2%
rate of change
SMC grade
D · 40
21.7% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
D · 40
SMC grade — 21.7% timeframe alignment
-13.2%
Rate of change (10d)
$63.00
Price target (+60.9%) · 7 analysts
99.5%
Institutional ownership

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap stored with these figures ($1.8B); this record does not say which day it was fetched, so no estimate for today is made from it.

Business activity: cleared (no excluded categories detected)

AAOIFI Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 2 of 2 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.05% 30.00% Pass(29.9pp buffer)
Interest-bearing investments 23.57% 30.00% Pass(6.4pp buffer)
Usmani Fail 1 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.22% 33.00% Pass(32.8pp buffer)
Interest-bearing investments 97.18% 33.00% Fail(64.2pp over)
Non-liquid assets 2.82% at least 20.00% Fail(17.2pp below the floor)
MSCI Fail 1 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.22% 33.33% Pass(33.1pp buffer)
Cash + interest-bearing securities 97.18% 33.33% Fail(63.9pp over)
Accounts receivable 97.18% 33.33% Fail(63.9pp over)
FTSE Fail 1 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.00% 33.33% Pass(33.3pp buffer)
Cash + interest-bearing securities 97.18% 33.33% Fail(63.8pp over)
Accounts receivable 97.18% 50.00% Fail(47.2pp over)

ℹ️ Dow Jones Islamic Market, MSCI M-Series, S&P Shariah divide by a trailing-average market cap (24- or 36-month) rather than today's. That price history is not collected for non-US listings, so these are reported as unverified — it reflects a missing input on our side, not anything about the company.

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

Usmani (% of total assets)debt ratio 32.8pts
MSCI Islamic Index (% of total assets)debt ratio 33.1pts
FTSE Shariah Global Equity Index Series (% of total assets)debt ratio 33.3pts
Usmani (% of total assets)investments ratio 64.2pts
MSCI Islamic Index (% of total assets)cash and interest ratio 63.9pts
MSCI Islamic Index (% of total assets)receivables ratio 63.9pts

The numbers the ratios are built from

Read from COAG's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period not measured — —
Interest-bearing debtShort and long-term borrowings $0 2026-09-30 no debt tag reported in 3+ years (treated as $0)
Cash and interest-bearing securitiesCash, equivalents and marketable securities $430.2M 2026-09-30 CashAndCashEquivalentsAtCarryingValue, MarketableSecuritiesCurrent
Total assetsBalance sheet total $442.7M 2026-09-30 Assets
Market capDenominator for AAOIFI $1.8B live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series not measured — —
24-month average market capDenominator for Dow Jones Islamic Market not measured — —
Non-permissible revenueInterest and excluded income not measured — —

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet as of 2026-09-30. Screened 2026-11-17.

Filing links appear after the next screen: this row was screened before filing citations were recorded.

  • Total assets$442.7M
    Assets · balance sheet as of 2026-09-30
  • Interest-bearing debt$0
    no debt tag reported in 3+ years (treated as $0) · balance sheet as of 2026-09-30
  • Cash and interest-bearing securities$430.2M
    CashAndCashEquivalentsAtCarryingValue, MarketableSecuritiesCurrent · balance sheet as of 2026-09-30
  • Receivables$0
    no receivables tag reported in 3+ years (treated as $0) · balance sheet as of 2026-09-30
  • Market cap$1.8B
    Market-data quote at screen time, 2026-11-17 · not a filing figure, so no link

What changed, and when

Verdict history for COAG. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for COAG has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Tracked investors holding COAG
InvestorFirmPositionWeightAs of
Ken Griffin Citadel Advisors $3M 0.0% 2026-09-30
Peter Brown Renaissance Technologies $2M 0.0% 2026-09-30
Israel Englander Millennium Management $0M 0.0% 2026-09-30
Paul Tudor Jones Tudor Investment Corp $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

54.9447.4539.9632.4724.982026-05-012026-08-122026-11-18

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
34.53
S2
36.05
S1
37.56
PIVOT
39.08
R1
40.59
R2
42.11
R3
43.62

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
28.41 – 49.71
±27.27% from 39.06, made 2026-11-18 · resolves 2026-11-25
SELL
from 18 indicators
78.7% of our last 25417 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.4% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

SELL
18 indicators
OscillatorsSTRONG SELL
0 buy · 4 neutral · 3 sell
Moving averagesBUY
6 buy · 0 neutral · 5 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)50.10NEUTRAL
Stochastic %K (14)27.27NEUTRAL
CCI (20)-22.03NEUTRAL
Williams %R (14)-72.73NEUTRAL
MACD (12,26,9)-0.47SELL
ROC (10)-13.17SELL
Momentum (10)-5.94SELL
EMA (10)40.13SELL
SMA (10)41.30SELL
EMA (20)39.56SELL
SMA (20)40.32SELL
EMA (30)39.01BUY
SMA (30)37.44BUY
EMA (50)38.73BUY
SMA (50)36.73BUY
EMA (100)37.28BUY
SMA (100)41.19SELL
EMA (200)37.24BUY

About Hemab Therapeutics Holdings, Inc.

Healthcare · Biotechnology

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.

hemab.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily RANGING 43
⏰ 4H RANGING 37
🕐 1H BEARISH 98
⏱ 15-Min RANGING 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-13.2%
Rate of change (10d)
3.0×
Volume vs its 20-day average
1.35
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.